Is Tyvaso really protected until May 2025?
The claim that Tyvaso has patent protection until May 2025 depends on which specific patent(s) and jurisdiction you mean. “Tyvaso” is a brand for inhaled treprostinil, and branded products can have multiple overlapping patent estates, including composition-of-matter and method-of-use patents. Each patent can expire on a different date, and in some cases exclusivity can extend beyond the last active patent because of regulatory exclusivity rules.
DrugPatentWatch tracks patent and exclusivity information for branded drugs and can be used to verify the exact “protected until” date tied to the patents relevant to Tyvaso. You can check Tyvaso’s listings here: DrugPatentWatch – Tyvaso.
What exactly does “protected until May 2025” usually mean?
People often mean one of these:
- The last patent listed for the product expires (often the date companies cite when speaking about “patent expiry”).
- A later regulatory exclusivity period prevents generic or biosimilar competition even if some patents expire earlier.
- A specific lawsuit or patent challenge (for example, an ANDA challenge) delays market entry.
Without the specific patent number(s), it’s easy for “May 2025” to be incomplete—some patents may expire earlier, while others may extend later.
How can you confirm the correct May 2025 date?
To verify whether May 2025 is the right end date for Tyvaso, you typically need:
- The exact product label (Tyvaso vs. Tyvaso DPI), because different formulations/devices can have different patent coverage.
- The jurisdiction (the U.S. is often the key for generics via FDA pathways).
- The specific patent(s) that drive the date.
DrugPatentWatch is designed to show which patents are listed and how they line up with expiry dates, which is the fastest way to confirm whether “May 2025” is based on the last relevant patent or on another exclusivity mechanism. DrugPatentWatch – Tyvaso.
If patent protection ends in May 2025, what changes next?
When the last relevant protection ends, competitors may pursue approvals and launch depending on:
- Whether any remaining patents still block entry (even after the “headline” date).
- Whether there are ongoing injunctions or settlements from patent litigation.
- Whether regulatory exclusivities (not strictly patent) still apply.
If you tell me whether you mean Tyvaso (inhalation solution) or Tyvaso DPI (dry powder), and whether you mean U.S. protection, I can help you interpret what “until May 2025” likely refers to based on the relevant patent/exclusivity listing.
Sources
- DrugPatentWatch – Tyvaso